Haoxi Health Technology Limited Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Haoxi Health Technology (HAO) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received formal notification from Nasdaq confirming compliance with Listing Rule 5550(a)(2), which mandates maintaining a minimum bid price of $1.00 per share for Class A ordinary shares.
The compliance was achieved after HAO's closing bid price remained at or above $1.00 per share for ten consecutive business days, spanning from January 27, 2025, to February 7, 2025. With this achievement, the bid price deficiency matter has been resolved and closed.
Haoxi Health Technology (HAO) ha riacquistato con successo la conformità ai requisiti di prezzo minimo di offerta di Nasdaq. L'azienda ha ricevuto una notifica formale da Nasdaq che conferma la conformità con la Regola di quotazione 5550(a)(2), che impone di mantenere un prezzo minimo di offerta di $1,00 per azione per le azioni ordinarie di Classe A.
La conformità è stata raggiunta dopo che il prezzo di chiusura dell'offerta di HAO è rimasto pari o superiore a $1,00 per azione per dieci giorni lavorativi consecutivi, dal 27 gennaio 2025 al 7 febbraio 2025. Con questo risultato, la questione della carenza di prezzo di offerta è stata risolta e chiusa.
Haoxi Health Technology (HAO) ha recuperado con éxito el cumplimiento del requisito de precio mínimo de oferta de Nasdaq. La compañía recibió una notificación formal de Nasdaq confirmando el cumplimiento de la Regla de listado 5550(a)(2), que exige mantener un precio mínimo de oferta de $1.00 por acción para las acciones ordinarias de Clase A.
El cumplimiento se logró después de que el precio de cierre de la oferta de HAO se mantuviera en o por encima de $1.00 por acción durante diez días hábiles consecutivos, abarcando del 27 de enero de 2025 al 7 de febrero de 2025. Con este logro, el problema de deficiencia del precio de oferta ha sido resuelto y cerrado.
하오시 헬스 테크놀로지 (HAO)는 나스닥의 최소 입찰 가격 요건을 성공적으로 회복했습니다. 회사는 클래스 A 보통주에 대해 주당 최소 입찰 가격이 $1.00 이상을 유지해야 한다는 나스닥 상장 규칙 5550(a)(2) 준수를 확인하는 공식 통지를 받았습니다.
HAO의 최종 입찰 가격이 2025년 1월 27일부터 2025년 2월 7일까지 10일 연속으로 주당 $1.00 이상을 유지하면서 금번 기준을 달성하였습니다. 이 성취로 인해 입찰 가격 결함 문제는 해결되고 종료되었습니다.
Haoxi Health Technology (HAO) a réussi à rétablir sa conformité avec l'exigence de prix d'offre minimum de Nasdaq. L'entreprise a reçu une notification formelle de Nasdaq confirmant la conformité avec la règle de cotation 5550(a)(2), qui impose de maintenir un prix d'offre minimum de 1,00 $ par action pour les actions ordinaires de classe A.
La conformité a été atteinte après que le prix de clôture des offres de HAO soit resté à ou au-dessus de 1,00 $ par action pendant dix jours ouvrables consécutifs, du 27 janvier 2025 au 7 février 2025. Avec cet accomplissement, la question de la carence en prix d'offre a été résolue et clôturée.
Haoxi Health Technology (HAO) hat erfolgreich die Compliance mit der Nasdaq-Mindestgebotsanforderung wiederhergestellt. Das Unternehmen erhielt eine formelle Mitteilung von Nasdaq, die die Einhaltung der Listing-Regel 5550(a)(2) bestätigt, welche die Aufrechterhaltung eines Mindestgebots von $1,00 pro Aktie für die Stammaktien der Klasse A vorschreibt.
Die Compliance wurde erreicht, nachdem der Schlusskurs des HAO für zehn aufeinanderfolgende Geschäftstage, vom 27. Januar 2025 bis zum 7. Februar 2025, bei oder über $1,00 pro Aktie blieb. Mit diesem Erfolg wurde die Angelegenheit der Angebotsmängel gelöst und abgeschlossen.
- Regained Nasdaq listing compliance, eliminating delisting risk
- Maintained share price above $1.00 for required compliance period
- Successfully resolved bid price deficiency issue
- Previous trading below $1.00 threshold indicates recent share price weakness
Insights
HAO's successful compliance with Nasdaq's minimum bid price requirement represents a critical regulatory milestone that substantially reduces near-term delisting risk. This development carries several important implications for investors:
- The sustained trading above
$1.00 for 10 consecutive days demonstrates improved market confidence and price stability, particularly significant for a small-cap company in the competitive online marketing sector. - Maintaining Nasdaq listing status preserves important benefits including market visibility, trading liquidity and access to institutional investors - essential elements for potential future capital raising.
- For Chinese companies listed on U.S. exchanges, maintaining listing compliance is particularly significant amid heightened regulatory scrutiny, serving as a positive signal of corporate governance and operational stability.
While this regulatory hurdle has been cleared, investors should note that the company must continue maintaining compliance with all Nasdaq listing requirements, including minimum bid price, to ensure long-term market presence. The resolution of this compliance issue allows management to refocus on operational execution and growth strategies in their core online marketing business.
BEIJING, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced that it received a formal notification from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company’s Class A ordinary shares, par value US
The Nasdaq staff made this determination of compliance after the closing bid price of the Company’s Ordinary Shares has been at
About Haoxi Health Technology Limited
Haoxi Health Technology Limited is an online marketing solution provider headquartered in Beijing, China, specializing in serving healthcare industry advertiser clients. The Company’s growth is driven by the rise of news feed ads and the rapid development of the healthcare sector. The Company offers one-stop online marketing solutions, especially in online short video marketing, helping advertisers acquire and retain customers on popular platforms in China, such as Toutiao, Douyin, WeChat, and Sina Weibo. The Company is dedicated to reducing costs, increasing efficiency, and providing easy online marketing solutions to advertisers. For more information, please visit: http://ir.haoximedia.com .
Forward-Looking Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, underlying assumptions, and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's forecast on market trends; the Company's future business development; the demand for and market acceptance for new services; expectation to receive customer orders for new services; the anticipated timing for the marketing and sales of new solutions; changes in technology; the Company's ability to attract and retain skilled professionals; client concentration; and general economic conditions affecting the Company's industry and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Investor Relations
WFS Investor Relations Inc.
Janice Wang, Managing Partner
Email: services@wealthfsllc.com
Phone: +86 13811768599
+1 628 283 9214
FAQ
What was the minimum bid price requirement HAO needed to meet for Nasdaq compliance?
How long did HAO need to maintain the minimum bid price to regain compliance?
What happens now that HAO has regained Nasdaq compliance?
When did HAO receive formal notification of compliance from Nasdaq?
